Quinn Opportunity Partners LLC Sells 1,110,778 Shares of Amarin Corporation PLC $AMRN

Quinn Opportunity Partners LLC trimmed its stake in Amarin Corporation PLC (NASDAQ:AMRN) by 95.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,461 shares of the biopharmaceutical company’s stock after selling 1,110,778 shares during the period. Quinn Opportunity Partners LLC’s holdings in Amarin were worth $948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of AMRN. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Amarin by 4.0% in the first quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,400 shares during the period. Banque Cantonale Vaudoise purchased a new position in Amarin during the 1st quarter worth $25,000. LCM Capital Management Inc raised its position in Amarin by 2.4% during the 1st quarter. LCM Capital Management Inc now owns 858,259 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 20,000 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of Amarin by 470.3% in the 1st quarter. Stonepine Capital Management LLC now owns 651,614 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 537,357 shares during the period. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Amarin by 449,522.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after buying an additional 1,811,574 shares during the period. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Price Performance

Shares of AMRN stock opened at $16.21 on Thursday. The business has a fifty day moving average of $16.96 and a 200 day moving average of $14.94. The firm has a market capitalization of $335.27 million, a price-to-earnings ratio of -6.51 and a beta of 0.68. Amarin Corporation PLC has a 1 year low of $7.08 and a 1 year high of $20.90.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.33). The business had revenue of $48.56 million for the quarter, compared to analysts’ expectations of $42.04 million. Amarin had a negative return on equity of 16.31% and a negative net margin of 38.01%. As a group, equities research analysts expect that Amarin Corporation PLC will post -0.15 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on AMRN. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a report on Wednesday, October 8th. Zacks Research downgraded shares of Amarin from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. Finally, Wall Street Zen raised shares of Amarin from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. One analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amarin currently has a consensus rating of “Sell” and a consensus target price of $12.00.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.